280 related articles for article (PubMed ID: 9774142)
1. Chemical synthesis and biological properties of novel fluorescent antifolates in Pgp- and MRP-overexpressing tumour cell lines.
Robson C; Wright KA; Twentyman PR; Lambert PA; Griffin RJ
Biochem Pharmacol; 1998 Oct; 56(7):807-16. PubMed ID: 9774142
[TBL] [Abstract][Full Text] [Related]
2. A comparison of rhodamine 123 accumulation and efflux in cells with P-glycoprotein-mediated and MRP-associated multidrug resistance phenotypes.
Twentyman PR; Rhodes T; Rayner S
Eur J Cancer; 1994; 30A(9):1360-9. PubMed ID: 7999426
[TBL] [Abstract][Full Text] [Related]
3. Rapid recovery of a functional MDR phenotype caused by MRP after a transient exposure to MDR drugs in a revertant human lung cancer cell line.
Gonzalez Manzano R; Versanvoort C; Wright K; Twentyman PR
Eur J Cancer; 1996 Nov; 32A(12):2136-41. PubMed ID: 9014757
[TBL] [Abstract][Full Text] [Related]
4. Modification by brefeldin A, bafilomycin A1 and 7-chloro-4-nitrobenz-2-oxa-1,3-diazole (NBD) of cellular accumulation and intracellular distribution of anthracyclines in the non-P-glycoprotein-mediated multidrug-resistant cell line COR-L23/R.
Rhodes T; Barrand MA; Twentyman PR
Br J Cancer; 1994 Jul; 70(1):60-6. PubMed ID: 7912544
[TBL] [Abstract][Full Text] [Related]
5. Modulation by acrolein and chloroacetaldehyde of multidrug resistance mediated by the multidrug resistance-associated protein (MRP).
Manzano RG; Wright KA; Twentyman PR
Clin Cancer Res; 1996 Aug; 2(8):1321-6. PubMed ID: 9816303
[TBL] [Abstract][Full Text] [Related]
6. Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A.
Coley HM; Twentyman PR; Workman P
Biochem Pharmacol; 1989 Dec; 38(24):4467-75. PubMed ID: 2604747
[TBL] [Abstract][Full Text] [Related]
7. Cross-resistance to antifolates in multidrug resistant cell lines with P-glycoprotein or multidrug resistance protein expression.
van Triest B; Pinedo HM; Telleman F; van der Wilt CL; Jansen G; Peters GJ
Biochem Pharmacol; 1997 Jun; 53(12):1855-66. PubMed ID: 9256160
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin.
Twentyman PR; Wright KA; Mistry P; Kelland LR; Murrer BA
Cancer Res; 1992 Oct; 52(20):5674-80. PubMed ID: 1327513
[TBL] [Abstract][Full Text] [Related]
9. Retention of activity by selected anthracyclines in a multidrug resistant human large cell lung carcinoma line without P-glycoprotein hyperexpression.
Coley HM; Workman P; Twentyman PR
Br J Cancer; 1991 Mar; 63(3):351-7. PubMed ID: 1672252
[TBL] [Abstract][Full Text] [Related]
10. Multidrug resistance-associated protein: a protein distinct from P-glycoprotein involved in cytotoxic drug expulsion.
Barrand MA; Bagrij T; Neo SY
Gen Pharmacol; 1997 May; 28(5):639-45. PubMed ID: 9184795
[TBL] [Abstract][Full Text] [Related]
11. A phenotype conferring selective resistance to lipophilic antifolates in Chinese hamster ovary cells.
Sharma RC; Assaraf YG; Schimke RT
Cancer Res; 1991 Jun; 51(11):2949-59. PubMed ID: 1674447
[TBL] [Abstract][Full Text] [Related]
12. An etoposide-resistant lung cancer subline overexpresses the multidrug resistance-associated protein.
Doyle LA; Ross DD; Ordonez JV; Yang W; Gao Y; Tong Y; Belani CP; Gutheil JC
Br J Cancer; 1995 Sep; 72(3):535-42. PubMed ID: 7669558
[TBL] [Abstract][Full Text] [Related]
13. Characterisation of multidrug-resistant Ehrlich ascites tumour cells selected in vivo for resistance to etoposide.
Nielsen D; Maare C; Eriksen J; Litman T; Friche E; Skovsgaard T
Biochem Pharmacol; 2000 Aug; 60(3):353-61. PubMed ID: 10856430
[TBL] [Abstract][Full Text] [Related]
14. A study of ethacrynic acid as a potential modifier of melphalan and cisplatin sensitivity in human lung cancer parental and drug-resistant cell lines.
Rhodes T; Twentyman PR
Br J Cancer; 1992 May; 65(5):684-90. PubMed ID: 1316774
[TBL] [Abstract][Full Text] [Related]
15. Characterisation of non-P-glycoprotein multidrug-resistant Ehrlich ascites tumour cells selected for resistance to mitoxantrone.
Nielsen D; Eriksen J; Maare C; Litman T; Kjaersgaard E; Plesner T; Friche E; Skovsgaard T
Biochem Pharmacol; 2000 Aug; 60(3):363-70. PubMed ID: 10856431
[TBL] [Abstract][Full Text] [Related]
16. Identification of anthracyclines and related agents that retain preferential activity over adriamycin in multidrug-resistant cell lines, and further resistance modification by verapamil and cyclosporin A.
Coley HM; Twentyman PR; Workman P
Cancer Chemother Pharmacol; 1989; 24(5):284-90. PubMed ID: 2547527
[TBL] [Abstract][Full Text] [Related]
17. Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates.
Bram E; Ifergan I; Shafran A; Berman B; Jansen G; Assaraf YG
Cancer Chemother Pharmacol; 2006 Dec; 58(6):826-34. PubMed ID: 16612649
[TBL] [Abstract][Full Text] [Related]
18. Effects of cyclosporin A and a non-immunosuppressive analogue, O-acetyl cyclosporin A, upon the growth of parent and multidrug resistant human lung cancer cells in vitro.
Twentyman PR; Wright KA; Wallace HM
Br J Cancer; 1992 Mar; 65(3):335-40. PubMed ID: 1313690
[TBL] [Abstract][Full Text] [Related]
19. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis.
Assaraf YG
Drug Resist Updat; 2006; 9(4-5):227-46. PubMed ID: 17092765
[TBL] [Abstract][Full Text] [Related]
20. Multidrug resistance: molecular mechanisms and clinical relevance.
Ling V
Cancer Chemother Pharmacol; 1997; 40 Suppl():S3-8. PubMed ID: 9272126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
